



9 November 2020

ASX ANNOUNCEMENT

AstraZeneca Selects SOZO for Second Large Renal Trial

Key Highlights

- **AstraZeneca has selected SOZO® to be used in a second Phase II trial to measure fluid volume in patients with chronic kidney disease.**
- **An additional 200 SOZO devices will be leased across 24 countries for the second AstraZeneca trial, bringing the total SOZO devices leased under the studies to 375.**
- **The trial will run for approximately 18 months and will generate in excess of \$2.0 million in revenue, bringing the total expected revenue under the studies to \$4.5 million.**

Brisbane, Australia – ImpediMed Limited (ASX:IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health, today announced a second contract valued at over \$2.0 million for its SOZO® Digital Health Platform to be used in a clinical trial being conducted for AstraZeneca, a global pharmaceutical company. The Phase II trial will use the SOZO devices to track patient fluid volume in an upcoming pharmaceutical study focused on chronic kidney disease. The study, which is scheduled to begin in January 2021 and run for approximately 18 months, will require approximately 200 additional devices globally.

The company previously announced in September 2020 that AstraZeneca will use SOZO to track patient fluid volume in a clinical trial focused on heart failure and chronic kidney disease. A combined 375 SOZO devices will now be leased across 31 countries for the two trials. Together, the trials are expected to generate in excess of \$4.5 million in revenue.

“AstraZeneca’s selection of SOZO for a second clinical trial that is focused on patients with chronic kidney disease provides important validation for our technology and directly aligns with one of our three strategic focus areas,” commented Richard Carreon, Managing Director and CEO of ImpediMed. “There are millions of people today living with chronic kidney disease, and we look forward to learning more about the impact this trial will have on improving patient care,” he continued.

The AstraZeneca study using SOZO will evaluate the efficacy, safety, and tolerability of a combination of two AstraZeneca drugs in patients with chronic kidney disease. This Phase II trial is scheduled to begin in January 2021. The trial is being run by a contract research organisation, on behalf of AstraZeneca.

Under the terms of the agreement, and in alignment with the Company’s SaaS business model, each device will have a monthly license fee for the duration of the study. ImpediMed will retain ownership of the devices at the conclusion of the trials.

SOZO is CE-Marked for renal failure. Nearly 750,000 patients per year in the U.S. and an estimated 2 million patients worldwide are affected by end-stage renal disease (ESRD). Those who live with ESRD are 1% of the U.S. Medicare population but account for 7% of the Medicare budget, or approximately US\$35 billion.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@weworldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.